Education
About Us
Working with TipRanks
Follow Us
IGC Pharma (IGC)
:IGC
IGC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.25 - $0.50
Previous CloseN/A
Volume646.33K
Average Volume (3M)229.77K
Market Cap
$25.75M
Enterprise Value$45.93M
Total Cash (Recent Filing)$470.00K
Total Debt (Recent Filing)$270.00K
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Aug 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding83,891,590
10 Day Avg. Volume221,928
30 Day Avg. Volume229,767
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)2.13
Price to Sales (P/S)0.00
P/FCF Ratio-21.09
Enterprise Value/Market Cap1.78
Enterprise Value/Revenue9.52
Enterprise Value/Gross Profit72.22
Enterprise Value/Ebitda-1.32
Forecast
1Y Price Target
$4.25Price Target Upside1316.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
IGC Pharma News
PremiumCompany Announcements
IGC Pharma Reports Transformative Year in Alzheimer’s Innovation
PremiumCompany Announcements
IGC Pharma Highlights Alzheimer’s Research Progress
Bulls Say, Bears Say
Bulls Say
Clinical TrialsIGC reported positive interim results from its Phase 2 trial for IGC-AD1, showing a significant reduction in agitation compared to placebo in patients with Alzheimer's disease.
Growth OpportunitiesThe company's strategic expansion into the $75 billion wellness industry with the launch of the Holiby brand offers new growth opportunities.
Market PotentialThe large market potential for Alzheimer's treatments presents high rewards despite the risks, given the growing number of Americans affected by the disease.
Bears Say
Market RisksThe large market potential for Alzheimer's disease treatment, due to the absence of a known cure and a growing number of patients, presents high rewards for the risks involved.
Ownership Overview
2.49% Insiders
1.50% Mutual Funds
0.11% Other Institutional Investors
95.11% Public Companies and Individual Investors
IGC FAQ
What was IGC Pharma’s price range in the past 12 months?
IGC Pharma lowest stock price was $0.25 and its highest was $0.50 in the past 12 months.
What is IGC Pharma’s market cap?
IGC Pharma’s market cap is $25.75M.
When is IGC Pharma’s upcoming earnings report date?
IGC Pharma’s upcoming earnings report date is Aug 06, 2025 which is in 31 days.
How were IGC Pharma’s earnings last quarter?
IGC Pharma released its earnings results on Jun 30, 2025. The company reported -$0.02 earnings per share for the quarter, the consensus estimate of -$0.02 by $0.
Is IGC Pharma overvalued?
According to Wall Street analysts IGC Pharma’s price is currently Undervalued.
Does IGC Pharma pay dividends?
IGC Pharma does not currently pay dividends.
What is IGC Pharma’s EPS estimate?
IGC Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IGC Pharma have?
IGC Pharma has 83,891,590 shares outstanding.
What happened to IGC Pharma’s price movement after its last earnings report?
IGC Pharma reported an EPS of -$0.02 in its last earnings report, expectations of -$0.02. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of IGC Pharma?
Currently, no hedge funds are holding shares in IGC
Company Description
IGC Pharma
IGC Pharma (IGC) is a biopharmaceutical company engaged in the development and commercialization of innovative therapies for the treatment of debilitating and life-altering medical conditions. The company's core focus is on leveraging its expertise in cannabinoid-based therapies to address unmet needs in areas such as Alzheimer’s disease, chronic pain, and other neurological disorders. IGC Pharma is dedicated to advancing its pipeline of proprietary research compounds and delivering effective solutions that improve patients' quality of life.
IGC Earnings Call
Q4 2025
0:00 / 0:00
Technical Analysis
NN
―
Rcm Technologies
―
Steel Partners Holdings
―
Mammoth Energy Services
―
FTAI Infrastructure Incorporation
―